Connor, Clark & Lunn Investment Management (CC&L)’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.3M | Buy |
|
|||||
|
2025
Q1 | $1.86M | Sell |
|
|||||
|
2024
Q4 | $1.95M | Sell |
|
|||||
|
2024
Q3 | $1.38M | Buy |
|
|||||
|
2024
Q2 | $1.07M | Buy |
|
|||||
|
2024
Q1 | $1.91M | Buy |
|
|||||
|
2023
Q4 | $769K | Sell |
|
|||||
|
2023
Q3 | $712K | Buy |
|
|||||
|
2023
Q2 | $563K | Buy |
|
|||||
|
2023
Q1 | $170K | Buy |
|
|||||
|
2022
Q4 | $69.3K | Sell |
|
|||||
|
2022
Q3 | $161K | Buy |
|
|||||
|
2022
Q2 | $80K | Sell |
|
|||||
|
2022
Q1 | $339K | Buy |
|
|||||
|
2021
Q4 | $909K | Sell |
|
|||||
|
2021
Q3 | $1.24M | Buy |
|
|||||
|
2021
Q2 | $801K | Buy |
|
|||||
|
2021
Q1 | $307K | Buy |
|
|||||
|
2017
Q4 | – | Sell |
|
|||||
|
2017
Q3 | $271K | Sell |
|
|||||
|
2017
Q2 | $629K | Buy |
|
|||||
|
2016
Q3 | – | Sell |
|
|||||
|
2016
Q2 | $120K | Sell |
|
|||||
|
2016
Q1 | $614K | Sell |
|
|||||
|
2015
Q4 | $1.26M | Buy |
|
|||||
|
2015
Q3 | $864K | Buy |
|
|||||
|
2015
Q2 | $380K | Buy |
|
|||||
|
2015
Q1 | $266K | Buy |
|
|||||
|
2014
Q4 | $159K | Buy |
|